Wednesday, December 19, 2012

New Compounding Pharmacy Regulations: The First


With the recent NECC meningitis tragedy, Congress as well as every state board of pharmacy is taking a hard look at how compounding pharmacy is regulated. Even though compounding has and will always be part of traditional pharmacy, it has become apparent that the NECC as well as similar “compounding pharmacies” are pushing the boundaries of vague legal descriptions, usually limited to a few sentences in each state’s pharmacy rule and regulations.
However, it’s hard to create new regulations for a specialty that’s so broad and vague. Before any new regulation is considered, we must first define compounding with great detail to make sure we’re all talking about the same thing. It’s apparent that most state boards of pharmacy have no idea who compounds, what they compound, and how much they compound (see the last two Compound News for more information). However, should they? If it’s part of our practice and not currently regulated differently, why would they?
So, what is compounding? What “types” of compounding will be affected by the new regulations. If I mix a few antibiotics and creams each week, am I a compounding pharmacy?
A few questions that need to be answered:
  1. Is there a difference between a sterile compounding pharmacy and a non-sterile compounding pharmacy? If so, are they regulated differently?
  2. Is a compounding pharmacy that ships thousands of “prescriptions” each month out of state a pharmacy or small drug manufacturer?
  3. Is there a % of sales cutoff for compounded prescriptions that determines if you are a compounding pharmacy?
  4. Is there a number cutoff for one particular compounded medication that determines if you are a drug manufacturer?
  5. Is a compounding-only pharmacy a pharmacy or small drug manufacturer? Should there be a new classification?
Those are just a few of many questions that need to be addressed thoroughly before any new regulations are considered. I hope that the state boards of pharmacy, Congress, and even the FDA don’t respond hastily because in the end, if you can’t define who the problem is, patients, pharmacies, and physicians will suffer.
Source found here

1 comment:

Anonymous said...

Thank you for the good writeup. It actually used to be a amusement account it.
Glance complex to far delivered agreeable from you!
By the way, how could we communicate?
my site: longerai